Apply to trial NCT06496048

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 3Drug trial

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of Lurbinectedin monotherapy or Lurbinectedin + Irinotecan combined therapy versus Topotecan comparator in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening